1. Home
  2. RGLS vs PNST Comparison

RGLS vs PNST Comparison

Compare RGLS & PNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • PNST
  • Stock Information
  • Founded
  • RGLS 2007
  • PNST 2007
  • Country
  • RGLS United States
  • PNST United States
  • Employees
  • RGLS N/A
  • PNST N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • PNST Blank Checks
  • Sector
  • RGLS Health Care
  • PNST Finance
  • Exchange
  • RGLS Nasdaq
  • PNST Nasdaq
  • Market Cap
  • RGLS 102.1M
  • PNST 111.5M
  • IPO Year
  • RGLS 2012
  • PNST N/A
  • Fundamental
  • Price
  • RGLS $1.55
  • PNST $0.42
  • Analyst Decision
  • RGLS Strong Buy
  • PNST Strong Buy
  • Analyst Count
  • RGLS 6
  • PNST 3
  • Target Price
  • RGLS $10.33
  • PNST $2.50
  • AVG Volume (30 Days)
  • RGLS 268.2K
  • PNST 204.4K
  • Earning Date
  • RGLS 11-07-2024
  • PNST 02-19-2025
  • Dividend Yield
  • RGLS N/A
  • PNST N/A
  • EPS Growth
  • RGLS N/A
  • PNST N/A
  • EPS
  • RGLS N/A
  • PNST N/A
  • Revenue
  • RGLS N/A
  • PNST $123,579,000.00
  • Revenue This Year
  • RGLS N/A
  • PNST $16.07
  • Revenue Next Year
  • RGLS N/A
  • PNST $19.19
  • P/E Ratio
  • RGLS N/A
  • PNST N/A
  • Revenue Growth
  • RGLS N/A
  • PNST 11.06
  • 52 Week Low
  • RGLS $1.08
  • PNST $0.36
  • 52 Week High
  • RGLS $3.79
  • PNST $5.59
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 49.06
  • PNST 33.74
  • Support Level
  • RGLS $1.49
  • PNST $0.36
  • Resistance Level
  • RGLS $1.62
  • PNST $0.45
  • Average True Range (ATR)
  • RGLS 0.11
  • PNST 0.10
  • MACD
  • RGLS -0.00
  • PNST 0.00
  • Stochastic Oscillator
  • RGLS 37.50
  • PNST 9.67

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About PNST Pinstripes Holdings Inc.

Pinstripes Holdings Inc is an experiential dining and entertainment concept combining exceptional Italian-American cuisine with bowling, bocce, and private events. It owns and operates around 17 restaurants in the USA. The company designs and constructs large-format locations that are each 26,000 to 38,000 square feet of interior space, plus additional outdoor patio space that includes outdoor dining, bocce courts, fire-pits, and decorative fountains.

Share on Social Networks: